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ABSTRACT 
Atherosclerosis is increased in type 2 diabetic patients but the precise mechanisms underlying 
this predisposition remain vague. Mice deficient for insulin receptor substrate 2 (IRS2) develop 
type 2-like diabetes and thus, provide a model to explore the molecular connection between 
deranged carbohydrate metabolism and atherosclerosis. To explore the relationship between 
defective insulin signalling and atherosclerosis, we have examined the development of 
atherosclerosis in the following groups of fat-fed mice: wild-type, diabetic Irs2-null (Irs2-/-), 
atherosclerosis-prone apolipoprotein E-null (apoE-/-), and doubly-deficient apoE-/-Irs2-/-. 
Surprisingly, glucose levels of apoE-/-Irs2-/- mice were comparable to those seen in wild-type 
and apoE-/- and significantly lower than in Irs2-/- mice. Irs2-/- and apoE-/-Irs2-/- were 
hyperinsulinemic compared to wild-type and apoE-/- mice. Atherosclerotic lesions were barely 
detectable in wild-type and Irs2-/- mice, which displayed moderate hypercholesterolemia (~280 
mg/dL). Notably, atherosclerosis was significantly enhanced in apoE-/-Irs2-/- compared with 
apoE-/- mice, although both models displayed similar levels of severe hypercholesterolemia 
(>600 mg/dL). Circulating insulin levels predicted atherosclerotic lesion burden in apoE-/-Irs2-/- 
mice. Our results suggest that hyperinsulinemia as a result of Irs2 genetic ablation contributes 
to increased atherosclerosis when combined with severe hypercholesterolemia (apoE-/-Irs2-/- 
mice) in the absence of hyperglycaemia, thus implicating IRS2 as an important modulator of 
murine hypercholesterolemia-dependent atherosclerosis. Future studies are necessary to 
determine whether IRS2 dysfunction may promote atherosclerosis in normoglycemic, pre-
diabetic patients with clinical manifestations of hyperinsulinemia and insulin resistance. 
KEYWORDS: Atherosclerosis, diabetes, hypercholesterolemia, insulin receptor substrate 2, 
insulin, insulin resistance, genetically-modified mice. 
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INTRODUCTION 
Diabetes mellitus affects approximately 100 million persons worldwide, with 90-95% of these 
patients suffering from type 2 diabetes (1). Diabetic patients have a 2 to 10-fold higher risk of 
atherosclerosis and cardiovascular disease than the general population (1,2). Type 2 diabetes 
and the metabolic syndrome are characterized by hyperglycemia, hyperinsulinemia, insulin 
resistance, obesity, hypertension and dyslipidemia. These factors produce vascular disorders 
which facilitate atherosclerotic lesion formation and plaque instability, and additionally, favor 
formation and persistence of thrombi (1,3-5). Both type 2 diabetes and metabolic syndrome are 
predicted to increase at alarming rates during the next 50 years due to the prevalence of 
unhealthy lifestyle habits (e. g., obesity and lack of physical exercise). Therefore, it is of 
utmost importance to develop relevant animal models to be used in unravelling the 
mechanisms which accelerate atherosclerosis in prediabetic individuals (eg., hyperinsulinemic, 
glucose intolerant) and diabetic patients. 
Disruption of the Irs2 gene in the mouse produces pathological alterations very similar to 
type 2 diabetes and metabolic syndrome, including insulin resistance, hyperinsulinemia, 
glucose intolerance, obesity, hypertension, and moderate hyperlipidemia (6-9). Analysis of 
Irs2-/- mice has revealed that IRS2 signals are required for proper development and function of 
pancreatic β-cells as well as for the central regulation of appetite (10,11). Indeed, beta cell-
specific overexpression of IRS2 promotes beta cell growth, survival, and insulin secretion that 
prevents diabetes in Irs2-/-, obese and streptozotocin-treated mice (12). 
These studies suggest that the Irs2-/- model provides an appropriate experimental setting 
to explore the influence of deranged carbohydrate metabolism on atherosclerosis. Thus, we 
intercrossed Irs2-/- with the atherosclerosis-prone apoE-/- mouse which spontaneously develops 
hypercholesterolemia and complex atherosclerotic lesions resembling those observed in 
humans and which can be accelerated by a high-fat cholesterol-rich diet (13). In this study, we 
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have examined diet-induced atherosclerosis in wild-type, Irs2-/-, apoE-/-, and doubly-deficient 
apoE-/-Irs2-/- mice.  
 
 
 
 
MATERIALS AND METHODS 
 
Mice, genotyping and diet. Care of animals was in accordance with institutional guidelines. 
Male Irs2-/-(C57BL/6J) (6) and female apoE-/- (C57BL/6J, Charles River) mice were crossbed 
to generate apoE-/-Irs2-/- mice. Genotyping for Irs2 and apoE was done by PCR analysis as 
previously described (6) and as indicated by The Jackson Laboratory (http://jaxmice.org), 
respectively. After weaning, mice were maintained on a low-fat standard diet (2.8% fat; 
Panlab, Barcelona, Spain). At 2 months of age, mice received for 4 weeks an atherogenic diet 
containing 10.8% total fat, 0.75% cholesterol (S4892-E010, Ssniff, Soest, Germany).  
 
Metabolic measurements. All measurements were performed with plasma of mice that were 
fasted overnight. Cholesterol, triglyceride and glucose levels were measured using enzymatic 
procedures (WAKO, St. Louis, USA). HDL-C and non-HDL-C were quantified after 
precipitation with Dextran-sulphate MgCl2 (SIGMA, St. Louis, USA) as described (14). 
Insulin levels were quantified by ELISA (Mercodia, Sweeden). For glucose tolerance test, mice 
were injected with glucose (intraperitoneally, 2g/Kg of body weight) and plasma glucose levels 
were measured during 2 hours. 
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Atherosclerosis quantification. Fat-fed mice were killed, and after perfusion in situ with PBS 
followed by 4% paraformaldehyde/PBS, the heart and aorta were removed and fixation 
continued for 24h. A researcher blinded to genotype quantified the extent of atherosclerosis by 
computer-assisted morphometric analysis of whole-mounted aortic arch and thoracic aorta 
stained with Oil Red O (0.2% Oil Red O in 80% MeOH), and of aortic root cross-sections 
(intima-to-media ratio) by as previously described (15). Differences in lesion area between 
males and females were not significant, therefore data from both sexes are shown.  
 
Immunohistochemical staining. Vascular smooth muscle cells (VSMCs) were identified with 
monoclonal alkaline phosphatase-conjugated anti-smooth muscle alpha-actin (SM alpha-actin) 
antibody (clone 1A4, 1/20 dilution, a-5691, SIGMA) using Fast Red substrate (SIGMA). 
Macrophages were identified with a rat monoclonal anti-Mac 3 IgG1 antibody (clone M3/84, 
1/200 dilution, sc-19991; Santa Cruz Biotechnology, California, USA), using a biotin-
conjugated goat anti-rat IgG-B secondary antibody (sc-2041, Santa Cruz Biotechnology) and 
ABC kit (VECTOR, Burlingame, USA) using DAB substrate (SEROTEC, Oxford, UK). Slides 
were counterstained with hematoxylin.  
 
Statistics. Data are presented as mean±SE. Differences among groups were evaluated by 1-
way ANOVA with Fisher’s post-hoc test (Statview, SAS institute, Cary, USA). The F-test was 
used to measure the quality (significance) of regression analysis. Statistical significance was 
taken at p≤0.05. 
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RESULTS 
 
Analysis of plasma glucose, insulin and lipid levels  
To investigate the influence of deranged carbohydrate metabolism on diet-induced 
atherosclerosis, we examined the following groups of mice challenged for 4 weeks with an 
atherogenic diet enriched with fat and cholesterol: wild-type (WT), Irs2-/-, apoE-/-, and apoE-/-
Irs2-/-. Consistent with published observations in the C57BL/6 background (6), many Irs2-/- 
died from diabetic complications between 12 and 16 weeks of age; a similar proportion of 
apoE-/-Irs2-/- animals also died during the same phase of our study. Glucose levels in fat-fed 
WT, apoE-/- and apoE-/-Irs2-/- mice were comparable but significantly lower than those in 
hyperglycaemic Irs2-/- mice (Fig. 1A). Fasting insulin levels were indistinguishable between 
Irs2-/- and apoE-/-Irs2-/-, but significantly higher than in WT and apoE-/- mice (Fig. 1B). Fat-
fed animals from all groups exhibited glucose intolerance, which was more severe in Irs2-/- 
mice (data not shown). Body weight in apoE-/- and Irs2-/- mice was comparable and higher than 
that of apoE-/-Irs2-/- mice (Fig. 1C). 
As expected, plasma cholesterol level under standard chow was lower in both groups of 
mice with intact apoE (WT: 98.8±4.1 mg/dL, Irs2-/-: 120±11.5 mg/dL) as compared with mice 
deficient for this gene (apoE-/-: 341.3±17.8 mg/dL, apoE-/-Irs2-/-: 330.7±58.5 mg/dL) (Fig. 2A). 
While plasma cholesterol remained essentially unchanged in fat-fed WT mice (129.2±20 
mg/dL), all groups of genetically-modified animals developed hypercholesterolemia, which 
reached highest values in apoE-/- (664±28 mg/dL) and apoE-/- Irs2-/- (600.3±45.3 mg/dL) as 
compared with Irs2-/- (278.0±24.6 mg/dL) mice. This rise in total cholesterol was mostly 
produced in the non-HDL cholesterol fraction, which was also lower in WT and Irs2-/- when 
compared to apoE-/- and Irs2-/-apoE-/- mice under either dietary regimen (Fig. 2A). Irs2-/- mice 
fed standard chow exhibited the highest level of HDL-cholesterol, which decreased upon high-
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fat feeding to reach levels similar to those seen in WT, apoE-/- and Irs2-/-apoE-/- mice. Only 
apoE-/- mice exhibited a modest but statistically significant increase in plasma triglycerides 
upon high-fat feeding (Fig. 2B). 
 
Accelerated atherosclerosis in fat-fed apoE-/-Irs2-/- mice can be predicted by high level of 
circulating insulin 
We next examined in the four groups of mice fed the high-fat diet for 4 weeks the development 
of atherosclerosis in en face aortic preparations stained with Oil Red O (Fig. 3A). Upon gross 
macroscopic examination, atherosclerotic lesions were largely absent within the aortic arch and 
thoracic aorta of WT and Irs2-/- mice. In contrast, apoE-/- mice exhibited clearly visible 
atheromas, particularly within the aortic arch region, consistent with numerous studies in this 
mouse model. These observations were corroborated by computer-assisted planimetric analysis 
which revealed a significant increase in aortic arch atherosclerotic lesion size in apoE-/-Irs2-/- 
versus apoE-/- mice (p<0.01), a tendency that was also noted within the thoracic aorta. 
Furthermore, quantification of the intima-to-media ratio (I/M) in transverse sections through 
the aortic sinus, a highly atherogenic vascular bed in the mouse, also demonstrated accelerated 
atherosclerosis in apoE-/-Irs2-/- mice (p=0.050 versus apoE-/-) (Fig. 4A). 
We carried out regression analysis to ascertain whether aortic arch atherosclerosis 
development correlated with metabolic parameters. As revealed by the F-test, atheroma size 
and circulating levels of glucose and cholesterol did not correlate in fat-fed apoE-/- and apoE-/-
Irs2-/- mice (data not shown). However, this test revealed a significant direct correlation 
between plasma insulin level and aortic arch atherosclerotic lesion size in apoE-/-Irs2-/- but not 
in apoE-/- mice (Fig. 5). 
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Neointimal VSMC and macrophage content is not altered in apoE-/-Irs2-/- versus apoE-/-
mice  
We next carried out immunohistochemical studies in aortic sinus cross-sections to identify 
neointimal macrophages and VSMCs, using antibodies against Mac3 (Fig. 4B) and SM alpha-
actin (Fig. 4C), respectively. These studies revealed that atheromas in apoE-/- and apoE-/-Irs2-/- 
mice consisted of fatty streaks with a similar cellular composition, with predominance of 
macrophages and lower VSMC content. Although the differences versus apoE-/- and apoE-/-
Irs2-/- mice did not reach statistical significance, the very small lesions in Irs2-/- mice had a 
tendency towards reduced macrophage content, possibly due to the presence of 
undifferentiated monocytes which do not exhibit Mac3 immunoreactivity. 
 
 
 
DISCUSSION 
 
In this study using genetically-modified mice, we provide evidence that severe 
hypercholesterolemia imposed on IRS2 deficiency (>600 mg/dL, fat-fed apoE-/-Irs2-/- mouse) 
aggravates atherosclerosis. These findings are consistent with recently published studies 
demonstrating that partial (16) or global (17) Irs2 inactivation accelerates atheroma 
development in apoE-/- mice, and also contribute novel insight into the mechanisms that link 
IRS2 deficiency to atherosclerosis: 1) we found that atherosclerotic lesions were largely absent 
in fat-fed hyperinsulinemic, hyperglycaemic Irs2-/- mice which presented more modest levels 
of plasma cholesterol (~280 mg/dL). Thus, in the absence of severe hypercholesterolemia, Irs2 
disruption is not sufficient to promote atherosclerosis in the mouse. This is in marked contrast 
with the observation that normocholesterolemic (~70 mg/dL) Irs2-/- mice display accelerated 
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neointimal lesion development upon mechanical injury of the femoral artery (18); 2) our 
regression analysis indicates that atherosclerosis predisposition in apoE-/-Irs2-/- mice can be 
predicted by circulating insulin levels; 3) in contrast, plasma glucose levels did not predict the 
burden of atherosclerosis in apoE-/-Irs2-/- mice, and atheromas were largely absent in fat-fed 
hyperglycaemic Irs2-/- mice. These findings highlight an important difference between type 1 
and type 2 diabetes, since sustained hyperglycaemia alone without secondary lipid 
abnormalities is sufficient to accelerate murine atherosclerosis in the setting of type 1 diabetes 
(19,20). Further evidence that hyperglycaemia is not a predisposing factors for type 2 diabetes-
induced atherosclerosis is provided by observations in various obesity-related models of 
diabetes and atherosclerosis (21-24); 4) we found that acceleration of atherosclerosis in apoE-/-
Irs2-/- mice is not accompanied by changes in neointimal VSMC and macrophage content in 
early fatty streaks. Due to the high mortality rate associated with development of diabetes 
under conditions of IRS2 deficiency, it was impossible to evaluate whether this genetic 
manipulation may affect lesion composition at advanced disease states (eg., old fat-fed apoE-/-
Irs2-/- versus apoE-/- mice), and to investigate the effects on atherosclerosis of long-term 
exposure of Irs2-/- mice to high-fat diet.  
Surprisingly, we observed that fasting hyperglycaemia and glucose intolerance was 
ameliorated in apoE-/-Irs2-/- in comparison with Irs2-/- mice, which did not appear to be related 
to a preservation of beta-cell mass (data not shown). Previous studies have shown that Irs2 
disruption upregulates the expression of lipogenic enzymes in the liver (25), which in turn 
enhances hepatic lipid uptake as well as lipogenesis. Given that apoE is the major ligand for 
hepatic lipoprotein and lipid clearance, the possibility exists that reduced plasma glucose in 
apoE-/-Irs2-/- versus Irs2-/- mice may reflect a compensatory increase in lipogenesis which 
maintains lipid homeostasis. 
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Studies in mice (26) and humans (27,28) have linked insulin signalling with increased 
lipid accumulation in macrophages and foam cell formation by enhanced CD36 receptor 
expression. Consistent with this, transplant of insulin receptor (IR)-null bone marrow into 
irradiated low-density lipoprotein receptor-null mice (Ldlr-/-) increased lipid uptake through the 
upregulation of CD36 and SRA, thereby aggravating atherosclerosis (29). In contrast, 
Baumgartl and co-workers reported that macrophage-specific deficiency of either IR or IRS2 
ameliorates atherosclerosis development in apoE-/- mice (17). Although the reasons for this 
apparent discrepancy are unclear, it appears that modulation of glucose and insulin signalling 
in macrophages plays a direct role in lipid deposition and foam cell formation in the vessel 
wall.  
Despite the presence of insulin resistance and maintenance on a high-fat diet, apoE-/-Irs2-
/- mice did not develop obesity during our study (Fig. 1C). In contrast, mice homozygous for 
the diabetes (Leprdb/db) and obesity (Lepob/ob) mutations display phenotypes of obesity-induced 
diabetes (30). When either of these models is combined with deficiency for apoE, 
atherosclerosis is enhanced in double mutants fed normal rodent chow and this tendency is 
further aggravated by high-fat regimen (21,23,24). Atherosclerosis is also increased in Ldlr-/-
Lepob/ob mice, although to a lesser extent than in apoE-/-Lepob/ob mice (22,23). Unlike these 
obese/diabetic models, atherosclerosis in apoE-/-Irs2-/- mice was not associated with either 
obesity or aggravated dyslipidemia. However, one common feature of all these models is 
hyperinsulinemia, suggesting that plasma insulin levels predict atherosclerotic lesion burden. 
However, it should be noted that insulin resistance and hyperinsulinemia do not enhance 
atherosclerosis in Ldlr-/- mice under conditions of very high hypercholesterolemia (up to 2000 
mg/dL) (31). Thus, these different murine models offer excellent tools for unraveling distinct 
molecular links between atherosclerosis development and various risk factors associated with 
diabetes and metabolic syndrome. 
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In conclusion, our findings suggest that hyperglycaemia and hyperinsulinemia are not 
sufficient to promote atherosclerosis under conditions of mild hypercholesterolemia (~280 
mg/dL, fat-fed Irs2-/- mice). However, when combined with severe hypercholesterolemia (>600 
mg/dL, fat-fed apoE-/-Irs2-/- mice), the systemic insulin resistance produced by the absence of 
IRS2 facilitates development of atherosclerosis in a manner that can be predicted by circulating 
insulin levels. Future studies are warranted to determine whether IRS2 dysfunction contributes 
to human atherosclerosis in individuals with hyperinsulinemia but without overt 
hyperglycaemia, and in type 2 diabetic patients with or without metabolic syndrome.  
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Figure 1: Analysis of body weight and plasma glucose and insulin levels. Mice received the 
atherogenic diet for 4 weeks. (A) Glucose level in WT (n=14, 6 females, 8 males), Irs2-/- (n=8, 
4 females, 4 males), apoE-/- (n=18, 7 females, 11 males) and apoE-/-Irs2-/- (n=7, 3 females, 4 
males) mice. (B) Insulin level in WT (n=7, 2 females, 5 males) Irs2-/- (n=6, 3 females, 3 
males), apoE-/- (n=10, 5 females, 5 males) and apoE-/-Irs2-/- (n=6, 3 females, 3 males) mice. 
(C) Body weight in WT (n=14, 6 females, 8 males), Irs2-/- (n=8, 4 females, 4 males), apoE-/- 
(n=10, 4 females, 6 males) and apoE-/-Irs2-/- (n=6, 3 females, 3 males) mice. Results represent 
the mean±SE.  
 
Figure 2: Analysis of plasma lipid levels. Mice were fed control chow until the age of 2 
months (white bars) and then were switched to the atherogenic diet for 4 weeks (black bars). 
Total cholesterol, HDL-cholesterol, non-HDL cholesterol and triglycerides were quantified in 
WT (n=14, 6 females, 8 males), Irs2-/- (n=8, 4 females, 4 males), apoE-/- (n=18, 7 females, 11 
males) and apoE-/-Irs2-/- (n=6, 3 females, 3 males) mice. Results represent the mean±SE. For 
simplicity, only relevant statistical comparisons are shown.  
Figure 3: Irs2-/-apoE-/- mice exhibit accelerated aortic atherosclerosis. Mice were sacrificed 
after 4 weeks of high-fat feeding and the aorta was processed for en face Oil-red O staining to 
quantify atherosclerotic lesion formation in the aortic arch and thoracic aorta by a researcher 
who was blinded to genotype. WT: n=14 (6 females, 8 males), Irs2-/-: n=8 (4 females, 4 
males), apoE-/-: n=16 (7 females, 9 males), apoE-/-Irs2-/-: n=7 (3 females, 4 males). Results 
represent the mean±SE. 
 
Figure 4: Immunohistochemical characterization of atherosclerotic lesions. Mice were 
maintained for 4 weeks on the atehrogenic diet and atherosclerosis in cross-sections through 
the aortic sinus was quantified by an operator who was blinded to genotype. Data for Irs2-/-, 
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apoE-/- and apoE-/-Irs2-/- are shown in yellow, red and blue, respectively. (A) Quantification of 
the intima-to-media ratio (for each mouse, average from 3 independent cross-sections), 
neointimal Mac3-immunoreactive macrophages and neointimal SM alpha-actin-
immunoreactive VSMCs. Results represent the mean±SE of 4 Irs2-/-, 8 apoE-/- and 5 apoE-/-
Irs2-/- mice. Representative images of Mac 3 (B) and SM alpha-actin (C) immunostaining are 
shown. The lower photomicrographs correspond to enlarged areas of the specimens shown on 
top. 
 
Figure 5: Plasma insulin levels predict the burden of atherosclerosis in apoE-/-Irs2-/- mice. 
Regression analysis of atheroma size within the aortic arch as a function of plasma insulin 
levels. Each point represents one animal. The F-test revealed a statistically significant 
correlation between plasma insulin levels and atheroma size only in apoE-/-Irs2-/- mice. 
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